Vu Thinh Toan, Rupasinghe Dhanushi, Khol Vohith, Chaiwarith Romanee, Tanuma Junko, Kumarasamy Nagalingeswaran, Khusuwan Suwimon, Somia IKetut Agus, Pujari Sanjay, Lee Man Po, Borse Rohidas T, Kiertiburanakul Sasisopin, Yunihastuti Evy, Azwa Iskandar, Choi Jun Yong, Chen Hsin-Pai, Ditangco Rossana, Avihingsanon Anchalee, Gani Yasmin, Ross Jeremy, Jiamsakul Awachana
Department of Community Health and Social Sciences, CUNY Graduate School of Public Health and Health Policy, New York, NY, USA.
The Kirby Institute, UNSW Sydney, Sydney, Australia.
AIDS Res Ther. 2025 Mar 4;22(1):29. doi: 10.1186/s12981-025-00718-8.
Data on the impact of World Health Organization (WHO)'s guideline changes and COVID-19 on ART initiation in the Asia-Pacific remain scarce. This study described temporal trends from HIV diagnosis to ART initiation from 2013 to 2023 and its associated factors.
Adults (≥ 18 years) diagnosed with HIV after 2013 in a regional observational cohort were included. Fine and Gray competing risk regression examined predictors of ART initiation (≥ 3 antiretroviral medications), accounting for those lost to follow-up or deceased before treatment considered as competing risks.
Among 14,968 participants, most were male (70.1%), with a median age of 36 years (interquartile range [IQR]: 28-44). At HIV diagnosis, median CD4 count was 208 cells/µL (IQR: 69-395), and median viral load was 86,296 copies/mL (IQR: 13,186-392,000). Over 85% of participants had initiated ART during the study period. Median time from HIV diagnosis to ART initiation differed across years of HIV diagnosis: 51 days (2013-2015), 28 days (2016-2019), and 26 days (≥ 2020). Factors associated with shorter time to ART initiation were higher country income-level (upper-middle: sub-distribution hazard ratio [SHR] = 1.34, 95% CI: 1.28, 1.40; high: SHR = 1.35, 95% CI: 1.28, 1.43; vs. lower-middle); HIV transmission via male-to-male contact (SHR = 1.06, 95% CI: 1.02, 1.11) or injection drug use (SHR = 1.23, 95% CI: 1.09, 1.38; vs. heterosexual contact); and later years of HIV diagnosis (2016-2019: SHR = 1.33, 95% CI: 1.28, 1.38; ≥ 2020: SHR = 1.40, 95% CI: 1.33, 1.48; vs. 2013-2015). Those with higher CD4 counts had longer time to ART start (350-499 cells/µL: SHR = 0.76, 95% CI: 0.67, 0.86; > 500 cells/µL: SHR = 0.55, 95% CI: 0.49, 0.61; vs. CD4 < 200 cells/µL).
Time to ART initiation from HIV diagnosis decreased after 2016, aligning with evolving WHO guidelines, and did not appear to be impacted by COVID-19. Optimizing treatment initiation during the treat-all era is crucial, especially among those with higher CD4 counts.
世界卫生组织(WHO)指南变化及新冠疫情对亚太地区抗逆转录病毒治疗(ART)启动的影响数据仍然匮乏。本研究描述了2013年至2023年从HIV诊断到ART启动的时间趋势及其相关因素。
纳入2013年后在一个区域观察性队列中被诊断为HIV的成年人(≥18岁)。Fine和Gray竞争风险回归分析了ART启动(≥3种抗逆转录病毒药物)的预测因素,将随访失访或在治疗前死亡者视为竞争风险。
在14968名参与者中,大多数为男性(70.1%),中位年龄为36岁(四分位间距[IQR]:28 - 44岁)。HIV诊断时,CD4细胞计数中位数为208个/µL(IQR:69 - 395),病毒载量中位数为86296拷贝/mL(IQR:13186 - 392000)。超过85%的参与者在研究期间开始了ART。从HIV诊断到ART启动的中位时间因HIV诊断年份而异:2013 - 2015年为51天,2016 - 2019年为28天,2020年及以后为26天。与ART启动时间较短相关的因素包括国家收入水平较高(中高收入:亚分布风险比[SHR]=1.34,95%置信区间[CI]:1.28,1.40;高收入:SHR = 1.35,95% CI:1.28,1.43;与中低收入相比);通过男男性接触传播HIV(SHR = 1.06,95% CI:1.02,1.11)或注射吸毒传播(SHR = 1.23,95% CI:1.09,1.38;与异性接触相比);以及较晚的HIV诊断年份(2016 - 2019年:SHR = 1.33,95% CI:1.28,1.38;2020年及以后:SHR = 1.40,95% CI:1.33,1.